Bioequivalence study of Amlodipine/Valsartan tablet
Not Applicable
Recruiting
- Conditions
- In the present study, the products will be administered to healthy volunteers.
- Registration Number
- IRCT20210519051345N54
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Age (18-59 years)
Exclusion Criteria
Smoking
History of cardiovascular disease, liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Amlodipine/Valsartan in calcium channel and angiotensin receptor inhibition?
How does the Sanamed Co. formulation compare to innovator drugs in treating hypertension and cardiovascular disease?
What biomarkers are used to assess bioequivalence in antihypertensive drug trials like IRCT20210519051345N54?
What adverse events are associated with Amlodipine/Valsartan combination therapy in healthy volunteers?
How does Amlodipine/Valsartan compare to other fixed-dose combinations in managing resistant hypertension?